Standard Biotools (LAB) Gross Margin (2010 - 2026)

Standard Biotools (LAB) has reported Gross Margin for 17 consecutive years, with 52.4% the latest figure, recorded in Q2 2026.

• On a quarterly basis, Gross Margin rose 357.0% year-over-year to 52.4% in Q2 2026; TTM through Jun 2026 was 50.49%, a 34.0% decrease from a year earlier, with the FY2025 full-year figure at 49.86%, up 54.0% from the prior year.
• Gross Margin was 52.4% for Q2 2026 at Standard Biotools, down from 53.48% in the prior quarter.
• Over five years, Gross Margin peaked at 54.9% in Q3 2024 and troughed at 23.58% in Q2 2022.
• A 5-year average of 47.19% and a median of 48.67% in 2025 frame the typical range for Gross Margin.
• Across the five-year window, Gross Margin tumbled 3820 bps in 2022 and surged 2559 bps in 2023, its largest moves.
• Over 5 years, Gross Margin stood at 41.33% in 2022, then advanced by 15 bps to 47.39% in 2023, then retreated by 3 bps to 45.84% in 2024, then rose by 4 bps to 47.83% in 2025, then gained by 10 bps to 52.4% in 2026.
• The last three Gross Margin figures came in at 52.4% (Q2 2026), 53.48% (Q1 2026), and 47.83% (Q4 2025), per Business Quant data.